1. Home
  2. NAMS vs NWBI Comparison

NAMS vs NWBI Comparison

Compare NAMS & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • NWBI
  • Stock Information
  • Founded
  • NAMS 2019
  • NWBI 1896
  • Country
  • NAMS Netherlands
  • NWBI United States
  • Employees
  • NAMS N/A
  • NWBI N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • NWBI Major Banks
  • Sector
  • NAMS Health Care
  • NWBI Finance
  • Exchange
  • NAMS Nasdaq
  • NWBI Nasdaq
  • Market Cap
  • NAMS 1.7B
  • NWBI 1.9B
  • IPO Year
  • NAMS N/A
  • NWBI N/A
  • Fundamental
  • Price
  • NAMS $25.50
  • NWBI $13.35
  • Analyst Decision
  • NAMS Strong Buy
  • NWBI Hold
  • Analyst Count
  • NAMS 6
  • NWBI 3
  • Target Price
  • NAMS $36.20
  • NWBI $12.67
  • AVG Volume (30 Days)
  • NAMS 1.4M
  • NWBI 713.5K
  • Earning Date
  • NAMS 02-06-2025
  • NWBI 01-21-2025
  • Dividend Yield
  • NAMS N/A
  • NWBI 5.99%
  • EPS Growth
  • NAMS N/A
  • NWBI N/A
  • EPS
  • NAMS N/A
  • NWBI 0.76
  • Revenue
  • NAMS $33,594,000.00
  • NWBI $487,913,000.00
  • Revenue This Year
  • NAMS $129.49
  • NWBI N/A
  • Revenue Next Year
  • NAMS N/A
  • NWBI $5.89
  • P/E Ratio
  • NAMS N/A
  • NWBI $17.58
  • Revenue Growth
  • NAMS 78.77
  • NWBI N/A
  • 52 Week Low
  • NAMS $10.50
  • NWBI $10.45
  • 52 Week High
  • NAMS $27.29
  • NWBI $15.42
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 62.30
  • NWBI 33.54
  • Support Level
  • NAMS $24.40
  • NWBI $14.15
  • Resistance Level
  • NAMS $26.95
  • NWBI $14.64
  • Average True Range (ATR)
  • NAMS 1.66
  • NWBI 0.37
  • MACD
  • NAMS 0.41
  • NWBI -0.17
  • Stochastic Oscillator
  • NAMS 81.51
  • NWBI 16.76

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About NWBI Northwest Bancshares Inc.

Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and banking business solutions, investment management, trust services and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.

Share on Social Networks: